Frontida BioPharm Caught Storing Toxic Waste Without a Permit | Adare Pharma Solutions

Frontida BioPharm Fined for Years of Hazardous Waste Violations
Corporate Misconduct Accountability Project

Frontida BioPharm Fined for Years of Hazardous Waste Violations

EPA found the Philadelphia pharmaceutical packager operated without permits, skipped inspections for three years, and mishandled toxic waste including mercury lamps and ignitable chemicals.

HIGH SEVERITY
TL;DR

Frontida BioPharm, a Philadelphia pharmaceutical packager owned by Adare Pharma Solutions since 2021, violated federal hazardous waste laws for years. The EPA found the company operated a hazardous waste storage facility without a permit, failed to conduct required weekly inspections for three years, improperly managed toxic materials including mercury-containing lamps and ignitable chemicals, and shipped hazardous waste without proper documentation. The company agreed to pay a $13,750 penalty and certified it corrected the violations.

This case shows how pharmaceutical companies can quietly violate environmental protections for years before detection.

$13,750
Total civil penalty paid by Frontida BioPharm
3 years
Duration company failed to conduct weekly hazardous waste inspections
200
Containers of rejected material without hazardous waste determination
6
Open containers of mercury-containing universal waste lamps found

The Allegations: A Breakdown

โš ๏ธ
Core Allegations
What they did · 8 points
01 Frontida BioPharm operated a hazardous waste storage facility without a permit. On March 1, 2023, the company accepted hazardous waste from its Orthodox facility, which is a Large Quantity Generator. Regulations only allow Very Small Quantity Generators to consolidate waste at Large Quantity Generator sites under specific conditions, not Small Quantity Generators like Frontida. high
02 The company failed to conduct weekly inspections of its hazardous waste accumulation area for three years, from March 1, 2020 to at least March 1, 2023. These inspections are required by federal regulations incorporated into Pennsylvania law to detect leaking containers and prevent environmental releases. high
03 Frontida failed to make waste determinations at the point of generation for multiple waste streams. The EPA inspector observed approximately 200 rejected material containers in the Reject Cage without hazardous waste determinations. Facility representatives stated rejected material accumulates for an unspecified period before any determination is made. high
04 The company mismanaged waste aerosol cans, with facility representatives admitting they were unsure how waste aerosol cans are managed and how previously generated waste aerosol cans had been disposed. The inspector observed in-use aerosol cans at the facility with no documented disposal procedures. medium
05 Frontida disposed of IPA-contaminated wipes as nonhazardous waste without providing any hazardous waste determination documentation. At the time of inspection, facility representatives stated these wipes are disposed as nonhazardous waste without proper characterization. medium
06 The company failed to file an exception report after 45 days when a designated facility did not sign manifest 024947115JJK for a shipment of D001 hazardous waste on May 17, 2023. There is no record of the required exception report being filed on July 2, 2023. medium
07 From March 1, 2020 to at least March 1, 2023, Frontida shipped hazardous waste from the facility to its Orthodox facility without documenting the shipments on Uniform Hazardous Waste Manifests. Facility representatives stated hazardous waste was shipped between facilities without manifest documentation during this entire three-year period. high
08 The EPA inspector observed six open containers of universal waste lamps containing mercury, which increases the risk of breakage and mercury release. Mercury is a potent neurotoxin that poses serious health risks. high
๐Ÿ”
Regulatory Failures
System weaknesses exposed · 6 points
01 Violations persisted for three years before EPA detection. The company failed to conduct weekly inspections and failed to document hazardous waste shipments from March 1, 2020 to at least March 1, 2023, demonstrating a prolonged period of undetected non-compliance. high
02 The EPA did not conduct a compliance evaluation inspection at the facility until March 1, 2023, allowing years of violations to continue undetected. The gap between violations beginning in 2020 and inspection in 2023 reveals limitations in regulatory oversight frequency. medium
03 Pennsylvania’s state environmental agency, PADEP, received notice of the enforcement action on October 24, 2024, more than a year and a half after the inspection. This extended timeline delayed state-level awareness and potential additional oversight. medium
04 The settlement was reached through an expedited process that allowed the company to neither admit nor deny the specific factual allegations. Only jurisdictional allegations were admitted, meaning no formal admission of the environmental lapses occurred. medium
05 No individual executives or managers faced personal liability for the operational decisions that led to years of violations. The settlement only named Frontida BioPharm, LLC as the corporate entity, with no accountability for individuals responsible. medium
06 The EPA based its enforcement on regulations from 2005, which were the last revisions Pennsylvania incorporated by reference on June 29, 2009. This means the state’s hazardous waste program may not reflect nearly two decades of updated federal standards. low
๐Ÿ’ฐ
Profit Over People
Cost-cutting at public expense · 6 points
01 Operating without a permit for storing waste from another facility allowed Frontida to avoid significant costs. Establishing and maintaining a permitted hazardous waste storage facility involves expenses for infrastructure, training, and administrative oversight that the company circumvented. high
02 Skipping weekly inspections for three years saved substantial labor costs. These inspections require dedicated staff time and meticulous record-keeping that the company avoided throughout the violation period. high
03 Failing to properly characterize waste streams like Reject Cage Material and IPA-contaminated wipes reduced analytical and disposal costs. Hazardous waste disposal is typically more expensive than non-hazardous waste disposal, creating financial incentive to misclassify materials. medium
04 The $13,750 penalty may be viewed as a minor cost of doing business when weighed against potential savings from years of non-compliance. For a commercial pharmaceutical packaging entity, this sum does not represent a significant financial deterrent against future violations. high
05 Shipping hazardous waste between facilities without manifests avoided documentation costs and simplified operations. The company saved on administrative labor by bypassing the cradle-to-grave tracking system designed to ensure proper waste handling. medium
06 Frontida BioPharm was acquired by Adare Pharma Solutions in 2021, during the period when violations were ongoing. The new ownership continued operations with existing compliance failures, suggesting inadequate due diligence or prioritization of environmental obligations during the acquisition. medium
โ˜ ๏ธ
Public Health and Safety
Environmental risks created · 8 points
01 Six open containers of universal waste lamps containing mercury posed direct contamination risks. Mercury is a potent neurotoxin, and storing lamps in open containers increases the risk of breakage and mercury release into the environment. high
02 The company stored hazardous wastes classified as D001 (ignitable), D002 (corrosive), and F003 (spent non-halogenated solvents like Isopropyl Alcohol). These materials can cause fires, chemical burns, and toxic exposures if not properly managed. high
03 Three years without weekly inspections meant potential leaks, deteriorating containment, or other hazardous conditions could have gone unnoticed and unaddressed. Early detection of problems is critical to preventing releases into soil, water, or air. high
04 Misclassifying hazardous waste as non-hazardous could have led to improper disposal in municipal landfills not designed to contain such materials. This creates risks of groundwater contamination and toxic emissions affecting surrounding communities. high
05 Improperly managed batteries can leak heavy metals or corrosive materials. The inspector observed two unlabeled containers of universal waste batteries and containers without accumulation start dates, indicating inadequate tracking and containment. medium
06 Waste aerosol cans were observed at the facility with no clear management procedures. Facility representatives admitted uncertainty about disposal methods, creating risks of pressurized container explosions or release of ignitable contents. medium
07 The facility is located at 7722 Dungan Road in Philadelphia, placing these hazardous waste risks in an urban environment with nearby residential areas. Potential spills, fires, or releases could directly impact local community members. high
08 Undocumented shipments of hazardous waste between facilities obscured the chain of custody and accountability. This lack of documentation made it impossible to verify that hazardous waste reached appropriate treatment, storage, or disposal facilities. medium
๐Ÿ˜๏ธ
Community Impact
Philadelphia neighborhood at risk · 4 points
01 The facility operates in Philadelphia at 7722 Dungan Road, placing hazardous waste management failures in an urban setting. Violations involving ignitable, corrosive, and mercury-containing wastes created risks for nearby residents and local ecosystems. high
02 Three years of uninspected hazardous waste storage areas meant potential environmental releases could have affected local soil, groundwater, or air quality. Communities rely on proper industrial oversight to protect their living environment. high
03 Improperly stored ignitable and corrosive wastes increased risks of fires, explosions, or dangerous chemical reactions. Such incidents could have affected not only the facility but also its immediate surroundings and emergency responders. medium
04 The EPA reserves the right to act if it determines an imminent and substantial endangerment to public health, public welfare, or the environment. This language acknowledges that the violations created real risks to the surrounding community that may require future intervention. medium
โš–๏ธ
Corporate Accountability Failures
Weak consequences for serious violations · 6 points
01 The $13,750 penalty for three years of violations may not serve as a meaningful deterrent. The fine amounts to roughly $4,583 per year of non-compliance, a sum that may be viewed as a minor business expense rather than a significant consequence. high
02 Frontida BioPharm did not admit to the specific factual allegations as part of the settlement. The company only admitted jurisdictional facts, meaning no formal admission of wrongdoing regarding the environmental and safety lapses occurred. medium
03 No individual executives, managers, or employees faced personal liability or penalties. The settlement only held the corporate entity accountable, allowing individuals responsible for operational decisions to avoid consequences. high
04 The expedited settlement process prioritized efficiency over thorough public reckoning. While this approach secured compliance quickly, it avoided deeper examination of the corporate culture that allowed systematic violations to persist. medium
05 The settlement allows the company to avoid federal tax deductions for the civil penalty. However, this provision does not address whether the penalty amount itself is sufficient to change behavior or deter future violations. low
06 The agreement required Frontida to certify that violations have been corrected, focusing on future compliance rather than accountability for past harm. No assessment of environmental damage or community exposure during the violation period was documented. medium
โฐ
Exploiting Delay
Time as a strategic asset · 4 points
01 Violations occurred from March 1, 2020 to at least March 1, 2023 before EPA detection. This three-year period of undetected non-compliance allowed the company to benefit from avoided compliance costs throughout that time. high
02 The EPA inspection occurred on March 1, 2023, but the settlement was not filed until April 21, 2025. This two-year gap between inspection and final resolution meant the company continued operating during the entire enforcement process. medium
03 Frontida submitted its response to the EPA inspection on September 1, 2023, six months after the inspection. This delay extended the period before formal enforcement proceedings began. low
04 The EPA did not notify Pennsylvania’s PADEP of the impending enforcement action until October 24, 2024, more than a year and a half after the inspection. This extended timeline delayed potential state-level enforcement or oversight. medium
๐Ÿ“Š
The Bottom Line
What this case reveals · 5 points
01 A pharmaceutical packaging company violated fundamental environmental protections for years in an urban Philadelphia neighborhood. The violations included operating without permits, skipping required inspections, and mishandling toxic materials. high
02 The $13,750 penalty for three years of hazardous waste violations demonstrates the limited financial consequences companies face for environmental non-compliance. Cost savings from avoided compliance may have exceeded penalty costs. high
03 No individuals faced accountability despite systematic failures in hazardous waste management. Only the corporate entity paid a penalty, allowing responsible decision-makers to avoid personal consequences. medium
04 The case illustrates how regulatory oversight gaps allow violations to persist for years before detection. Three years of weekly inspection failures and undocumented waste shipments went undetected until a 2023 compliance evaluation. high
05 The expedited settlement resolved violations efficiently but avoided deeper examination of why a pharmaceutical company owned by a larger corporation systematically failed to follow environmental laws. Questions about corporate culture and priorities remain unaddressed. medium

Timeline of Events

September 1989
Frontida BioPharm submits notification to PADEP as a small quantity generator of hazardous waste and receives RCRA ID No. PAD002277150
March 2020
Company begins three-year period of failing to conduct weekly hazardous waste inspections and failing to document waste shipments on manifests
2021
Adare Pharma Solutions acquires Frontida BioPharm, with violations continuing under new ownership
March 2023
EPA representatives conduct Compliance Evaluation Inspection at the Philadelphia facility and discover multiple violations
May 2023
Frontida ships D001 hazardous waste via manifest 024947115JJK; designated facility never signs the manifest
July 2023
Frontida fails to file required exception report 45 days after May shipment was not confirmed
September 2023
Frontida provides response to EPA’s inspection findings via email
October 2024
EPA sends letter to Pennsylvania PADEP giving prior notice of enforcement action
April 2025
Expedited Settlement Agreement and Final Order filed; Frontida agrees to pay $13,750 penalty and certifies violations corrected

Direct Quotes from the Legal Record

QUOTE 1 Operating without a permit allegations
“On March 1, 2023, Respondent operated the Facility without a permit by accepting HW from its Orthodox facility, which is a Large Quantity Generator (LQG) of HW. Consolidation of HW by mutually owned facilities is only allowable, with certain exceptions and requirements, by Very Small Quantity Generators to LQGs. Respondent is an SQG that accepted and stored HW from an LQG without a permit.”

๐Ÿ’ก This shows the company knowingly violated permitting rules by accepting hazardous waste it was not authorized to store.

QUOTE 2 Three years without inspections allegations
“From March 1, 2020 to at least March 1, 2023, Respondent failed to conduct weekly inspections of its HW accumulation area as required by 25 Pa. Code ยง 262a.10”

๐Ÿ’ก The company skipped mandatory safety inspections for three full years, creating prolonged risk of undetected leaks or releases.

QUOTE 3 200 containers without determination allegations
“Facility representatives stated that rejected material is accumulated in the Reject Cage for an unspecified period of time before a HW determination is made. The Inspector observed approximately 200 rejected material containers in the Reject Cage at the time of the Inspection for which a HW determination had not been made.”

๐Ÿ’ก This reveals a systematic failure to determine if materials are hazardous before storage, violating a fundamental requirement of waste management.

QUOTE 4 Uncertainty about aerosol can disposal allegations
“Waste Aerosol Cans โ€“ the Inspector observed in-use aerosol cans at the Facility at the time of the Inspection. The Facility representatives indicated they were unsure how waste aerosol cans are managed by the Facility and unsure how previously generated waste aerosol cans had been disposed.”

๐Ÿ’ก Company representatives admitted they did not know how they manage or dispose of potentially hazardous aerosol cans.

QUOTE 5 IPA wipes disposed as non-hazardous allegations
“IPA-contaminated Wipes โ€“ At the time of the Inspection, Facility representatives stated that IPA-contaminated wipes are disposed as nonhazardous waste and did not provide any HW determination documentation for the waste stream.”

๐Ÿ’ก The company disposed of chemical-contaminated wipes without proper testing, risking improper disposal of hazardous materials.

QUOTE 6 Three years of undocumented shipments allegations
“From March 1, 2020 to at least March 1, 2023, Respondent failed to document HW shipments on Uniform Hazardous Waste Manifests in violation of 25 Pa Code ยง 262a.10 which incorporates by reference 40 C.F.R. ยง 262.20(a)(1). Facility representatives stated that during this time period, HW was shipped from the Facility to the Respondent’s Orthodox facility without documentation on HW manifests.”

๐Ÿ’ก The company admitted to three years of shipping hazardous waste without required tracking documents, eliminating accountability for where waste went.

QUOTE 7 Open containers of mercury lamps health
“At the time of the Inspection, the Inspector observed six (6) open containers of UW lamps in violation of 25 Pa. Code ยง 266b, which incorporates by reference 40 C.F.R. ยง 273.13(d)(1).”

๐Ÿ’ก Open containers of mercury-containing lamps increase breakage risk and potential mercury release, a potent neurotoxin.

QUOTE 8 Multiple labeling failures allegations
“At the time of the Inspection, the Inspector observed six (6) unlabeled containers of UW lamps in violation of 25 Pa. Code ยง 266b, which incorporates by reference 40 C.F.R. ยง 273.14(e).”

๐Ÿ’ก Unlabeled hazardous waste containers prevent proper identification and emergency response if spills or accidents occur.

QUOTE 9 No tracking of accumulation time allegations
“At the time of the Inspection, the Inspector observed six (6) containers of UW lamps and two (2) containers of UW batteries that were not marked with start accumulation dates and the Facility did not have another method to track accumulation time, in violation of 25 Pa. Code ยง 266b, which incorporates by reference 40 C.F.R. ยง 273.15(c).”

๐Ÿ’ก Without tracking accumulation time, hazardous materials can be stored longer than legally allowed, increasing deterioration and release risks.

QUOTE 10 Settlement considered statutory factors accountability
“Complainant and Respondent agree that settlement of this matter for a total penalty of THIRTEEN THOUSAND SEVEN HUNDRED AND FIFTY DOLLARS ($13,750.00) is in the public interest. In calculating this amount, Complainant considered the statutory factors set forth in Section 3008(a)(3) of RCRA, 42 U.S.C. ยง 6928(a)(3), and with specific reference to EPA’s October 1990 RCRA Civil Penalty Policy, as revised in June 2003 (RCRA Penalty Policy), and the 2021 RCRA Expedited Settlement Agreement Pilot.”

๐Ÿ’ก The EPA determined this modest penalty was appropriate despite three years of violations, raising questions about deterrent effectiveness.

QUOTE 11 No admission of factual allegations accountability
“In signing this Agreement, Respondent: admits the jurisdictional allegations in this Agreement; neither admits nor denies the specific factual allegations in this Agreement, except as provided in the jurisdictional admission above”

๐Ÿ’ก The settlement allowed the company to pay a fine without admitting it actually committed the violations described by EPA inspectors.

QUOTE 12 Violations certified as corrected accountability
“By its signature below, Respondent certifies, subject to civil and criminal penalties for making a false submission to the United States Government, that (1) the alleged violations have been corrected, and (2) any documentation or information provided to EPA was true and accurate.”

๐Ÿ’ก The company certified it fixed the problems but faces no documented assessment of harm caused during years of non-compliance.

QUOTE 13 EPA reserves right to address imminent danger community
“EPA reserves the right to commence action against any person, including Respondent, in response to any condition which EPA determines may present an imminent and substantial endangerment to the public health, public welfare, or the environment.”

๐Ÿ’ก The EPA kept authority to take further action if serious environmental or health threats are discovered, suggesting ongoing concerns.

QUOTE 14 Late payment consequences accountability
“Late payment of the agreed upon penalty may subject Respondent to interest, administrative costs and late payment penalties in accordance with 40 C.F.R. ยง 13.11.”

๐Ÿ’ก The agreement includes provisions for late payment penalties, but the base penalty itself remains modest relative to the violations.

QUOTE 15 Federal tax deduction prohibition accountability
“agrees to bear its own costs and attorney’s fees; and agrees not to deduct for federal tax purposes the civil penalty assessed in this Consent Agreement and Final Order.”

๐Ÿ’ก The company cannot write off the penalty as a business expense on federal taxes, though the amount is still relatively small.

Frequently Asked Questions

โ“What did Frontida BioPharm do wrong?
Frontida BioPharm violated federal hazardous waste laws for years at its Philadelphia facility. The company operated a hazardous waste storage facility without a permit, failed to conduct required weekly inspections for three years, mismanaged toxic materials including mercury-containing lamps and ignitable chemicals, shipped hazardous waste without proper documentation, and failed to determine if various waste streams were actually hazardous before disposing of them.
โ“How long did these violations continue?
The most serious violations continued for three years, from March 1, 2020 to at least March 1, 2023. During this entire period, the company failed to conduct required weekly inspections of hazardous waste areas and shipped hazardous waste between facilities without proper manifests. The EPA did not discover these violations until a compliance inspection on March 1, 2023.
โ“What types of hazardous materials were mishandled?
The company mishandled multiple types of hazardous waste including ignitable materials (D001), corrosive materials (D002), spent solvents like Isopropyl Alcohol (F003), mercury-containing universal waste lamps, batteries, aerosol cans, rejected pharmaceutical powders, and IPA-contaminated wipes. The EPA found six open containers of mercury lamps, which is a potent neurotoxin.
โ“What was the penalty for three years of violations?
Frontida BioPharm agreed to pay a civil penalty of $13,750 to settle the case. This amounts to roughly $4,583 per year of non-compliance. The company also certified that it corrected the violations, but did not have to admit to the specific factual allegations as part of the settlement.
โ“Did anyone face personal consequences?
No. The settlement only named Frontida BioPharm, LLC as the corporate entity. No individual executives, managers, or employees faced personal liability or penalties for the operational decisions that led to years of environmental violations.
โ“Where is this facility located and who could have been affected?
The facility is located at 7722 Dungan Road in Philadelphia, Pennsylvania, placing these hazardous waste violations in an urban environment with nearby residential areas. The improper management of ignitable, corrosive, and mercury-containing wastes created potential risks for local residents, workers at the facility, and the surrounding ecosystem.
โ“Who owns Frontida BioPharm?
Frontida BioPharm was acquired by Adare Pharma Solutions in 2021. This means the violations continued under Adare’s ownership from 2021 through at least March 2023, suggesting the new owner either failed to conduct adequate environmental due diligence or chose not to prioritize bringing the facility into compliance.
โ“Why did it take so long for the EPA to discover these problems?
The violations persisted for three years before the EPA conducted a compliance evaluation inspection on March 1, 2023. This gap reveals limitations in how frequently regulatory agencies can inspect facilities. With limited resources, the EPA cannot continuously monitor all regulated facilities, creating opportunities for prolonged non-compliance.
โ“What happened to the 200 containers without hazardous waste determinations?
The EPA inspector found approximately 200 containers of rejected pharmaceutical material in the Reject Cage without hazardous waste determinations. Facility representatives admitted they accumulate rejected material for an unspecified period before making any hazardous waste determination. Without proper testing, these materials could have been disposed of improperly, potentially contaminating landfills not designed for hazardous waste.
โ“What can concerned citizens do?
Citizens can request public records about facilities in their area through state environmental agencies, attend public comment periods for facility permits, report suspected environmental violations to the EPA or state regulators, support stronger environmental enforcement through advocacy organizations, and pressure companies to prioritize environmental compliance over cost-cutting. The EPA maintains a public database of enforcement actions where community members can research local facilities.
Post ID: 3922  ยท  Slug: epa-adare-frontida-pharma-hazardous-waste-violations  ยท  Original: 2025-05-17  ยท  Rebuilt: 2026-03-20

You can read this Expedited Settlement Agreement between the EPA and Frontida (Adare) by visiting the EPA’s website: https://yosemite.epa.gov/OA/RHC/EPAAdmin.nsf/Filings/C65F6629B20A15FB85258C730078F4DF/$File/Frontida%20BioPharm%20LLC_RCRA%20C%20ESA_April%2021%202025.pdf

๐Ÿ’ก Explore Corporate Misconduct by Category

Corporations harm people every day โ€” from wage theft to pollution. Learn more by exploring key areas of injustice.

Aleeia
Aleeia

I'm the creator this website. I have 6+ years of experience as an independent researcher studying corporatocracy and its detrimental effects on every single aspect of society.

For more information, please see my About page.

All posts published by this profile were either personally written by me, or I actively edited / reviewed them before publishing. Thank you for your attention to this matter.

Articles: 1683